Pharma Focus Asia

Shorla Oncology Introduced Novel SH-105 for the Treatment of Breast And Ovarian Cancer

Shorla Oncology has unveiled a groundbreaking drug, SH-105, designed to address breast and ovarian cancer.

SH-105 marks a significant advancement as it offers a ready-to-dilute alternative to a long-standing drug traditionally available in freeze-dried powder. The liquid formulation of SH-105 eliminates the requirement for reconstitution of the powder, leading to improved efficiency. 

This innovation not only streamlines the preparation process but also mitigates the risks associated with the intricate steps involved in powder reconstitution. The transition to a liquid form is poised to enhance the overall convenience and safety of administering the drug.

The groundbreaking drug, SH-105, is set to provide hospital pharmacists and patients with access to a distinct ready-to-administer injectable product. With its unique characteristics, SH-105 is anticipated to streamline adoption swiftly once it receives approval. 

According to the American Cancer Society, over 350,000 women are projected to receive a breast cancer diagnosis in the U.S. in 2023. SH-105 stands out among the numerous oncology drugs progressing through advanced pipeline.

This innovation offers a differentiated solution, ensuring convenience for both healthcare professionals and patients.
 

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024